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Objectives. We sought to examine whether patients with stable
coronary artery disease (CAD) have increased platelet reactivity
and an enhanced propensity to form monocyte-platelet aggre-
gates.
Background. Platelet-dependent thrombosis and leukocyte in-
filtration into the vessel wall are characteristic cellular events
seen in atherosclerosis.
Methods. Anticoagulated peripheral venous blood from 19
patients with stable CAD and 19 normal control subjects was
incubated with or without various platelet agonists and analyzed
by whole blood flow cytometry.
Results. Circulating degranulated platelets were increased in
patients with CAD compared with control subjects (mean
[6SEM] percent P-selectin–positive platelets: 2.1 6 0.2 vs. 1.5 6
0.2, p < 0.01) and were more reactive to stimulation with
1 mmol/liter of adenosine diphosphate (ADP) (28.7 6 3.9 vs.
16.1 6 2.2, p < 0.01), 1 mmol/liter of ADP/epinephrine (51.4 6 4.6
vs. 37.5 6 3.8, p < 0.05) or 5 mmol/liter of thrombin receptor
agonist peptide (TRAP) (65.7 6 6.8 vs. 20.2 6 5.1, p < 0.01).
Patients with stable CAD also had increased circulating
monocyte-platelet aggregates compared with control subjects
(percent platelet-positive monocytes: 15.3 6 3.0 vs. 6.3 6 0.9, p <
0.01). Furthermore, patients with stable CAD formed more
monocyte-platelet aggregates than did control subjects when their
whole blood was stimulated with 1 mmol/liter of ADP (50.4 6 4.5
vs. 28.1 6 5.3, p < 0.01), 1 mmol/liter of ADP/epinephrine (60.7 6
4.3 vs. 48.0 6 4.8, p < 0.05) or 5 mmol/liter of TRAP (67.6 6 5.7
vs. 34.3 6 7.0, p < 0.01).
Conclusions. Patients with stable CAD have circulating acti-
vated platelets, circulating monocyte-platelet aggregates, in-
creased platelet reactivity and an increased propensity to form
monocyte-platelet aggregates.
(J Am Coll Cardiol 1998;31:352–8)
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The pathophysiology of atherosclerosis involves thrombosis
and inflammation (1–3), conditions in which cellular activation
plays a predominant role. Traditionally these two cellular
processes have been studied independently of each other.
However, the heterotypic interaction between platelets and
leukocytes has recently become a focus of attention (4–10).
It is well established that serologic markers of platelet
activation are present in acute coronary artery syndromes
(2,11–13). However, direct evidence of hyperreactive or
“primed” platelets in stable coronary artery disease (CAD) is
lacking. Furthermore, recent evidence points to a major role
for leukocytes (14,15) and humoral inflammatory mediators in
the pathogenesis of coronary atherosclerosis (1,16–18).
P-selectin (also known as CD62P, previously known as
GMP-140 and PADGEM protein), a component of the plate-
let alpha granule membrane, is translocated to the surface
membrane on platelet activation (19,20). P-selectin mediates
the binding of platelets to leukocytes (21,22). Leukocytes have
been associated with platelets at sites of hemorrhage (23) and
during atherogenesis (1). P-selectin–mediated circulating
leukocyte-platelet aggregates have been noted after exposure
to oxidized low density lipoprotein (24) and cigarette smoke
(25), both of which are known risk factors for the development
of atherosclerosis. Recent reports have suggested an increase
in leukocyte–platelet interactions in patients with unstable
angina (10) and in those who have had percutaneous translu-
minal coronary angioplasty (9).
In this study, we used whole blood flow cytometry to
investigate platelet activation and leukocyte-platelet aggrega-
tion in patients with stable CAD. Whole blood flow cytometry
has the advantage of directly analyzing individual cells in their
native milieu with minimal artifactual cellular activation (26).
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Methods
Study group. The protocol was approved by the Commit-
tee for the Protection of Human Subjects in Research at the
University of Massachusetts Medical Center. The study group
consisted of patients undergoing outpatient cardiac catheter-
ization at the University of Massachusetts Medical Center for
symptomatic stable angina. This group of patients was chosen
to ensure documentation by angiography of the extent of CAD.
No subject had rest pain or a myocardial infarction within 3
months of the study. Sampling occurred before administration
of heparin or contrast agents. The characteristics of the study
group are displayed in Table 1. The control group consisted of
healthy nonsmoking adult volunteers (10 men and 9 women)
not taking any medication and who had not taken any anti-
platelet agent for at least 10 days before sampling. Coronary
artery disease was excluded in the control group by a self-
reported lack of symptoms suggestive of CAD or a docu-
mented cardiac event.
Monoclonal antibodies. S12 and G1 (Centocor) are di-
rected against different epitopes on P-selectin (22). S12 was
biotinylated as previously described (27). Y2/51 (DAKO) is
directed against glycoprotein (GP) IIIa (28) and was purchased
conjugated to fluorescein isothiocyanate (FITC). 7E3 (courte-
sy of Dr. Barry Coller, Mt. Sinai Medical School, New York,
New York) is directed against the GPIIb-IIIa complex (29) and
was FITC-conjugated with QUICK TAG Kit (Boehringer
Mannheim). BEAR1 (Immunotech) is directed against the M
chain of CD11b (MAC-1) (30) on leukocytes and was pur-
chased FITC-conjugated. S12, G1, Y2/51, 7E3 and BEAR1 are
all immunoglobulin (Ig) G murine antibodies.
Whole blood flow cytometry. Platelet activation state. The
method has been previously described in detail (31). There
were no centrifugation, gel filtration, vortexing or stirring steps
that could artifactually activate platelets. Blood from patients
and control subjects was drawn into a sodium citrate Vacu-
tainer (Becton Dickinson). Within 15 min of drawing, the
blood was diluted 1:4 in modified HEPES-Tyrode’s buffer (137
mmol/liter NaCl, 2.8 mmol/liter KCl, 1 mmol/liter MgCl2, 12
mmol/liter NaHCO3, 0.4 mmol/liter Na2HPO4, 0.35% bovine
serum albumin, 10 mmol/liter HEPES, 5.5 mmol/liter glucose),
pH 7.4, containing the peptide glycyl-L-prolyl-L-arginyl-L-
proline (Calbiochem) at a concentration of 2.5 mmol/liter to
prevent fibrin polymerization (27) and either 1) no agonist; 2)
adenosine diphospate (ADP), 1 mmol/liter or 10 mmol/liter
(BIO/DATA); 3) ADP, 1 mmol/liter with epinephrine, 1 mmol/
liter (BIO/DATA) or ADP, 10 mmol/liter with epinephrine, 10
mmol/liter; 4) thrombin receptor activating peptide (TRAP), 5
mmol/liter or 30 mmol/liter (Calbiochem); or 5) purified human
alpha-thrombin (provided by Dr. John W. Fenton II, New
York Department of Health, Albany, New York), 2 U/ml.
After 10 min, all samples were fixed at 22°C for 20 min with
1% formaldehyde (final concentration). After fixation, samples
were diluted 10-fold in modified Tyrode’s buffer, pH 7.4. The
samples were then incubated at 22°C for 20 min with a
near-saturating concentration of FITC-conjugated monoclonal
antibody Y2/51 and a saturating concentration of biotinylated
monoclonal antibody S12, followed by incubation at 22°C for
20 min with 30 mg/ml of phycoerythrin-streptavidin (Jackson
ImmunoResearch). The platelet surface expression of P-selectin
is calcium-independent (32).
As previously described (27), samples were analyzed in an
EPICS Profile flow cytometer (Coulter Cytometry). Analysis
was performed within 4 h of fixation, at which time the
epitopes are still stable (26). The flow cytometer was equipped
with a 500 mW argon laser (Cyonics) operated at 15 mW with
an emission wavelength of 488 nm. The fluorescence of FITC
and phycoerythrin was detected using 525-nm and 575-nm
bandpass filters, respectively. After identification of platelets
by gating on both Y2/51-FITC positivity (i.e., GPIIIa positivity)
and their characteristic light scatter, binding of the biotinylated
monoclonal antibody S12 was determined by analyzing 5,000
individual platelets for phycoerythrin fluorescence. The per-
centage of P-selectin–positive platelets before and after plate-
let activation was defined as the percentage of platelets that
had a phycoerythrin fluorescence greater than a threshold
determined by 99% of platelets incubated with purified biotin-
Table 1. Patient Characteristics
Age (yr) 62 6 3
Male 13 (68%)
Hypertension 17 (89%)
Diabetes 6 (32%)
Current smoker 0
Hypercholesterolemia (.230 mg/dl) 6 (32%)
Family history of CAD 4 (21%)
Previous MI 6 (32%)
Previous PTCA 5 (26%)
LVEF (%) 55 6 2.3
Extent of CAD
Single vessel 16 (84%)
Double vessel 3 (16%)
Medications
Aspirin 19 (100%)
Beta-blocker 19 (100%)
Calcium channel blocker 14 (79%)
Oral nitrates 11 (58%)
ACE inhibitor 6 (32%)
Data presented are mean value 6 SEM or number (%) of patients. ACE 5
angiotensin-converting enzyme; CAD 5 coronary artery disease; LVEF 5 left
ventricular ejection fraction; MI 5 myocardial infarction; PTCA 5 percutaneous
transluminal coronary angioplasty.
Abbreviations and Acronyms
ADP 5 adenosine diphosphate
CAD 5 coronary artery disease
FITC 5 fluorescein isothiocyanate
GP 5 glycoprotein
Ig 5 immunoglobulin
RANTES 5 regulated on activation normal T cell expressed presumed
secreted
TRAP 5 thrombin receptor activating peptide
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ylated mouse IgG (Boehringer Mannheim) rather than biotin-
ylated S12.
Monocyte-platelet aggregates/neutrophil-platelet aggregates.
Blood was diluted 1:4 in modified HEPES-Tyrode’s buffer, pH
7.4, containing the FITC-conjugated monoclonal antibody
7E3, 2 mg/ml, and either 1) no agonist; 2) ADP, 1 mmol/liter or
10 mmol/liter; 3) ADP, 1 mmol/liter with epinephrine, 1
mmol/liter, or ADP, 10 mmol/liter with epinephrine, 10 mmol/
liter; 4) TRAP, 5 mmol/liter or 30 mmol/liter; or 5) purified
human alpha-thrombin, 2 U/ml. After 10 min, the samples
were fixed at 22°C for 10 min with 1.1% formaldehyde and
1.43 Hanks balanced saline solution (GIBCO), then diluted
4.6-fold with distilled water.
The samples were then analyzed in an EPICS Profile flow
cytometer. Analysis was performed within 4 h of fixation. The
fluorescence of FITC was detected using a 525-nm bandpass
filter. Monocytes and neutrophils were identified by their
characteristic light scatter properties (Fig. 1, upper panel).
Platelet-positive monocytes and neutrophils before and after
ex vivo activation were identified by binding of the FITC-
conjugated GPIIb-IIIa–specific monoclonal antibody 7E3 (Fig.
1, lower panel). The percentage of platelet-positive monocytes
and neutrophils before and after ex vivo activation was defined
as the percentage of monocytes and neutrophils that had FITC
fluorescence greater than a threshold determined by 99% of
monocytes and neutrophils incubated with FITC-mouse IgG
(Boehringer Mannheim) rather than FITC-7E3. One thousand
monocytes and 5,000 neutrophils were counted.
The monocyte-platelet and neutrophil-platelet aggregates
were P-selectin–dependent because, consistent with previous
studies (22), the formation of these aggregates was completely
blocked by 7.5 mg/ml of the P-selectin–specific monoclonal
antibody G1 (Fig. 2).
Monocyte activation. Blood was diluted 1:4 in modified
HEPES-Tyrode’s buffer, pH 7.4, containing a saturating con-
centration of the FITC-conjugated CD11b-specific monoclonal
antibody BEAR1 and fixed at 22°C for 10 min with 1%
formaldehyde. The samples were then analyzed in an EPICS
Profile flow cytometer. Monocytes were identified by their
characteristic light scatter properties. The fluorescence of
FITC-BEAR1 was detected using a 525-nm bandpass filter.
Background binding, obtained from parallel samples run with
FITC-mouse IgG, was subtracted from each test sample.
Statistics. Data were analyzed using the paired t test.
Results
Circulating activated platelets and circulating leukocyte-
platelet aggregates. Unstimulated peripheral blood from pa-
tients with stable CAD contained increased numbers of surface
P-selectin–positive platelets compared with peripheral blood
from normal control subjects (mean [6SEM] 2.1 6 0.2 vs.
1.4 6 0.2, p , 0.01) (Fig. 3). Furthermore, peripheral blood
from patients with stable CAD as compared with normal
control subjects contained increased numbers of circulating
monocyte-platelet aggregates (15.3 6 3.0 vs. 6.3 6 0.9, p ,
0.01) (Fig. 3), but no significant increase in the presence of
circulating neutrophil-platelet aggregates (6.8 6 1.2 vs. 5.6 6
1.0, p 5 0.10) (Fig. 3).
Platelet reactivity. As determined by the platelet surface
expression of P-selectin, platelets from patients with stable
Figure 1. Whole blood flow cytometric analysis of monocyte-platelet
and neutrophil-platelet aggregates in normal donors. Monocytes and
neutrophils were identified by their characteristic light scatter proper-
ties (upper panel). Platelet-positive monocytes and platelet-positive
neutrophils were identified by binding of FITC-conjugated GPIIb-
IIIa–specific monoclonal antibody 7E3 (lower panels). Addition of 2
U/ml of thrombin in the presence of 2.5 mmol/liter glycyl-L-prolyl-L-
arginyl-L-proline (an inhibitor of fibrin polymerization) resulted in
platelet binding to most monocytes and neutrophils.
Figure 2. Monocyte-platelet and neutrophil-platelet aggregates in
peripheral blood of normal control subjects incubated with or without
TRAP (5 mmol/liter [hatched bars] or 30 mmol/liter [solid bars]) in
the presence or absence (open bars) of the P-selectin-specific mono-
clonal antibody G1. Data shown are mean value 6 SEM, n 5 4.
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CAD were significantly more reactive to ex vivo agonist
stimulation than were platelets from normal control subjects
(Fig. 4). Platelets from patients with stable CAD as compared
with those from control subjects were more likely to degranu-
late in response to stimulation with a low concentration of
ADP (1 mmol/liter) (28.7 6 3.9 vs. 16.1 6 2.2, p , 0.01), a low
concentration of ADP (1 mmol/liter) and concomitant epi-
nephrine (1 mmol/liter) (51.4 6 4.6 vs. 37.5 6 3.8, p , 0.05)
and a low concentration of TRAP (5 mmol/liter) (65.7 6 6.8 vs.
20.2 6 5.1, p , 0.01) (Fig. 4). No significant differences in the
platelet surface expression of P-selectin were observed be-
tween patient and control platelets stimulated with maximal
concentrations of agonists (ADP, 10 mmol/liter; ADP, 10
mmol/liter, with epinephrine, 10 mmol/liter; TRAP, 30 mmol/
liter) (Fig. 4), demonstrating that the differences observed with
the use of low agonist concentrations were not due to an
increased amount of available platelet P-selectin in the pa-
tients.
Propensity to form leukocyte-platelet aggregates. In addi-
tion to the increased monocyte-platelet aggregates present in
the peripheral circulation of patients with stable CAD,
monocyte-platelet aggregates were more likely to form in
patients with stable CAD than in control subjects in response
to ex vivo agonist stimulation (Fig. 5). Stimulation of periph-
eral whole blood from patients with stable CAD as compared
with control subjects by a low concentration of ADP (1
mmol/liter) resulted in significantly more monocyte-platelet
aggregates (50.4 6 4.5 vs. 28.1 6 5.3, p , 0.01). Similar results
were seen when peripheral whole blood from patients with
stable CAD and normal control subjects was stimulated with a
low concentration of ADP (1 mmol/liter) and concomitant
epinephrine (1 mmol/liter) (60.7 6 4.3 vs. 48.0 6 4.8, p , 0.05)
or a low concentration of TRAP (5 mmol/liter) (67.6 6 5.7 vs.
34.3 6 7.0, p , 0.01) (Fig. 5). As was observed with platelet
reactivity (Fig. 4), no significant differences between patients
with stable CAD and control subjects were seen in the
propensity to form monocyte-platelet aggregates when high
concentrations of agonists (ADP, 10 mmol/liter; ADP 10
mmol/liter with epinephrine, 10 mmol/liter; TRAP, 30 mmol/
liter) were used (Fig. 5).
No significant differences between patients and control
subjects were noted in the propensity to form neutrophil-
platelet aggregates in response to stimulation with any of the
following agonists: 1) ADP, 1 mmol/liter; 2) ADP, 10 mmol/
liter; 3) ADP, 1 mmol/liter with epinephrine, 1 mmol/liter; 4)
ADP, 10 mmol/liter with epinephrine, 10 mmol/liter; 5) TRAP,
5 mmol/liter; 6) TRAP, 30 mmol/liter (Fig. 6).
Figure 3. Platelet surface P-selectin, monocyte-platelet aggregates and
neutrophil-platelet aggregates circulating in the peripheral blood of
patients with stable CAD (solid bars) and control subjects (open bars),
as determined by whole blood flow cytometry. *p , 0.01. Data shown
are mean value 6 SEM, n 5 19.
Figure 4. Platelet reactivity of patients with stable CAD (solid bars)
and control subjects (open bars), as determined by platelet surface
expression of P-selectin in response to exogenous agonist stimulation.
Epi 5 epinephrine. *p , 0.01. †p , 0.05. Data shown are mean
value 6 SEM, n 5 19.
Figure 5. Monocyte-platelet aggregates in the blood of patients with
stable CAD (solid bars) and control subjects (open bars), as deter-
mined by whole blood flow cytometry after ex vivo agonist stimulation.
Epi 5 epinephrine. *p , 0.01. †p , 0.05. Data shown are mean
value 6 SEM, n 5 19.
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Monocyte activation. There was no significant difference in
the binding of the activation-dependent anti-CD11b monoclo-
nal antibody BEAR1 to the surface of monocytes from patients
with stable CAD compared with control subjects (Fig. 7).
Subgroup analysis. There were no significant differences
between patients with or without hyperlipidemia or between
patients with or without diabetes with respect to 1) circulating
activated platelets; 2) platelet reactivity; 3) circulating
monocyte-platelet aggregates; 4) circulating neutrophil-
platelet aggregates; 5) propensity to form monocyte-platelet
aggregates; and 6) propensity to form neutrophil-platelet
aggregates.
Discussion
Platelet degranulation in patients with stable CAD. This
study directly demonstrates circulating degranulated platelets
and circulating monocyte-platelet aggregates in patients with
stable CAD. Previous studies of platelet function in patients
with coronary atherosclerosis have focused on patients with
acute coronary artery syndromes and active ischemia presum-
ably due to thrombosis within the coronary vessels (11,33–35).
These studies measured platelet secretory products and the
assays used were prone to artifactual platelet activation (36).
Flow cytometry is a direct method for the measurement of
platelet function, avoids in vitro artifactual platelet activation
and assesses the activation state of individual platelets (26,31).
Flow cytometry has been used to study platelets from patients
with CAD undergoing angioplasty (37–40) and to a limited
extent in patients with unstable angina (41). The present study
supports the usefulness of flow cytometry in studying platelets
from patients with stable CAD.
Our study not only demonstrates the presence of circulating
degranulated platelets in patients with stable CAD, but also
provides evidence of enhanced platelet reactivity as demon-
strated by the increased platelet surface expression of
P-selectin in response to stimulation with low concentrations of
agonists (Fig. 4). In patients with stable CAD, full stimulation
with ADP, ADP with epinephrine or TRAP resulted in a
similar number of P-selectin–positive platelets as those found
in control subjects. Thus, the increased platelet reactivity in
patients with stable CAD is not due to an increased amount of
available platelet P-selectin, but to an alteration in the intra-
cellular platelet environment, which makes them more respon-
sive to agonist stimulation. The cellular mechanisms responsi-
ble for these “primed” platelets remain unknown. Although
alterations in platelet nitric oxide production are associated
with CAD (42), the use of oral nitrates in 58% of the subjects
in this study makes decreased nitric oxide production an
unlikely explanation for the increased platelet responsiveness.
Furthermore, alterations in platelet surface receptors are
unlikely to be involved in the mechanism because similar
results were obtained with ADP, epinephrine and TRAP, each
of which is known to stimulate platelets through a different
receptor.
P-selectin is rapidly cleared from the surface of circulating
degranulated platelets (43). Thus, the detection of circulating
P-selectin–positive platelets in patients with stable CAD must
be due to a process of ongoing platelet degranulation because
the sampling of the patients’ blood was not temporally related
to an ischemic event, nor did it occur immediately distal to an
injured vessel.
In a group of patients with large-vessel peripheral vascular
disease, Davi et al. (44) reported that diabetes, hypercholes-
terolemia and hypertension, but not vascular disease per se,
are associated with platelet activation in vivo. Although it did
not reach statistical significance, a trend for increased throm-
boxane A2 biosynthesis was noted in Davi’s study for patients
with peripheral artery disease but without diabetes, hypercho-
lesterolemia or hypertension. Davi et al. used a radioimmuno-
assay of a major metabolite of thromboxane A2, 11-dehydro-
thromboxane B2, to detect platelet activation, an assay system
different from the whole blood flow cytometric assay used in
the present study. Furthermore, their study group consisted of
Figure 7. Monocyte surface CD11b in patients with stable CAD (solid
bars) and control subjects (open bars), as determined by whole blood
flow cytometry. p 5 NS. Data shown are mean value 6 SEM, n 5 19.
Figure 6. Neutrophil-platelet aggregates in the blood of patients with
stable CAD (solid bars) and control subjects (open bars), as deter-
mined by whole blood flow cytometry after ex vivo agonist stimulation.
Epi 5 epinephrine. p 5 NS. Data shown are mean value 6 SEM, n 5
19.
356 FURMAN ET AL. JACC Vol. 31, No. 2
PLATELETS AND MONOCYTE-PLATELET AGGREGATES IN CAD February 1998:352–8
patients with mild to moderate large-vessel peripheral artery
disease in contrast to the patients in the current study with
angiographically documented significant stenoses of moderate
sized coronary arteries. Fitzgerald et al. (11) report normal
thromboxane A2 synthesis in a group of patients with stable CAD,
a group of patients similar to the group of patients in the present
study.
Monocyte-platelet aggregates in patients with stable CAD.
In addition to identifying increased circulating degranulated
platelets and increased platelet reactivity in patients with stable
CAD, we demonstrate that this patient group has increased
circulating monocyte-platelet aggregates and an increased
propensity to form monocyte-platelet aggregates (Fig. 3 and
5). Our assay used the monoclonal antibody 7E3 to identify
platelets adherent to leukocytes. It has been reported that 7E3
binds to CD11b/CD18 (MAC-1) on the surface of monocytes
(45,46). However, our assay does not detect significant binding
of 7E3 to monocytes, as demonstrated by the almost complete
inhibition of monocyte-platelet aggregates by the P-selectin–
specific monoclonal antibody G1 (Fig. 2).
Platelet adhesion to monocytes and neutrophils is mediated
by the platelet surface expression of P-selectin (21,22), which
binds to P-selectin glycoprotein ligand-1 on leukocytes (47–
49). Thus, the increased circulating monocyte-platelet aggre-
gates observed in this study may simply reflect the presently
described increased platelet degranulation in patients with
stable CAD. Leukocyte-platelet aggregates have also been
identified in the whole blood of patients undergoing cardio-
pulmonary bypass (8) or hemodialysis (50). More recently,
neutrophil-platelet aggregates have been identified in the
peripheral blood of patients with unstable angina (10) and
monocyte-platelet and neutrophil-platelet aggregates in the
coronary sinus of patients undergoing coronary angioplasty (9).
The exact physiologic significance of monocyte-platelet
aggregation is unknown, but it may represent targeting of both
cell types to appropriate inflammatory or hemostatic sites (6).
Functional changes in one cell type by another have also been
demonstrated. For example, platelets have been shown to
supply cholesterol to monocytes, which may then mature into
lipid-laden macrophages (51). P-selectin on the surface of
activated platelets induces the expression of tissue factor in
monocytes (52). The binding of P-selectin to monocytes in the
area of vascular injury may be an initiator of thrombosis (52).
Thus, Palabrica et al. (53) have demonstrated that P-selectin–
mediated platelet adhesion to leukocytes is important in
promoting fibrin deposition within a growing thrombus. More
recently, Weyrich et al. (54) have shown that platelet surface
P-selectin can regulate monocyte chemokine synthesis in con-
cert with the platelet chemokine RANTES (regulated on
activation normal T cell expressed presumed secreted). Our
study did not demonstrate enhanced formation of neutrophil-
platelet aggregates in patients with stable CAD, a finding
consistent with recent reports that monocyte-platelet aggre-
gates form more easily than neutrophil-platelet aggregates
(6–8).
Study limitations. A limitation of this study is that platelets
and leukocyte-platelet aggregates were sampled in the periph-
eral circulation, not at the diseased vessel wall where cellular
activation presumably occurs. Thus, the circulating degranu-
lated platelets, circulating monocyte-platelet aggregates, in-
creased platelet reactivity and increased propensity to form
monocyte-platelet aggregates may not be wholly reflective of
local events within the coronary vasculature. Furthermore, our
control group consisted of healthy adults without significant
cardiac risk factors. Therefore, the differences in platelet
function and monocyte-platelet aggregation between the pa-
tients with stable CAD and the control subjects may not be
caused by the presence of atherosclerosis in the patients, but
may be due in part to the presence of hypertension, hyperlip-
idemia or diabetes or the use of beta-blockers, angiotensin-
converting enzyme inhibitors or calcium channel blockers. In
our laboratory, aspirin does not affect the platelet surface
expression of P-selectin or P-selectin–dependent monocyte-
platelet aggregates and neutrophil-platelet aggregates in re-
sponse to activation with TRAP or thrombin in normal volun-
teers (data not shown). Our data are consistent with previous
reports (55,56) that aspirin does not affect the platelet surface
expression of P-selectin, because alpha granule secretion is
independent of the arachidonic acid pathway (55). Although
aspirin may affect platelets from patients with CAD differently
from those of normal control subjects, its use by patients in this
study would then have resulted in an underestimation of the
presently described difference between normal control subjects
and patients with stable CAD.
Conclusions. In this study we demonstrate that patients
with stable CAD have circulating degranulated platelets, cir-
culating monocyte-platelet aggregates, increased platelet reac-
tivity and an increased propensity to form monocyte-platelet
aggregates. The question as to whether the degree of increased
platelet reactivity and monocyte-platelet aggregation corre-
lates with specific clinical events in these patients is currently
being addressed in a large prospective study.
We thank Barry S. Coller, MD and John W. Fenton II, PhD for generously
providing reagents.
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